| |
| |
 Triomune 30/40 Product: Triomune Tablets
Drug Name:
Stavudine + Lamivudine + Nevirapine
Packaging Type:Packets
of 30 tablets
Manufacturer: Cipla
| Triomune 40 Prices (Stavudine 40 mg +
Lamivudine 150 mg + Nevirapine 200 mg) |
| 30
tablets of Triomune 40 |
US$61.00 |
 Buy Triomune 40 |
| 60
tablets of Triomune 40 |
US$122.00 |
Buy Triomune 40 |
| 90
tablets of Triomune 40 |
US$183.00 |
Buy Triomune 40 |
Why is this medication prescribed?
Triomune is a combination of 3 drugs commonly used in the management
of Human Immunodeficiency Virus (HIV) infection.
Nevirapine is a non-nucleoside reverse
transcriptase inhibitor. It acts by directly inhibiting reverse transcriptase.
Stavudine and
lamivudine belong to the nucleoside analogue class of antiretroviral drugs.
Both act by terminating the growth of the DNA chain and inhibiting the
reverse transcriptase of HIV.
With the availability of this combination
formulation, patients may be better able to adhere to triple drug regimens, thereby
enhancing compliance.
How should this medicine be used?
Triomune ? 30: one tablet twice a day for patients weighing < 60 kg
Triomune ? 40: one tablet twice a day for patients weighing > 60 kg
Triomune should not be administered to patients who have just
initiated therapy with nevirapine.
This is because an initial lead-in dosing of 200 mg
nevirapine once a day for 2 weeks is recommended.
What side effects can this medication cause?
Triomune may cause side effects. Tell your doctor if one
of these symptoms is severe or does not go away:
- headache
- fatigue
- diarrhea
- upset stomach
- loss of appetite
- feeling dizzy
- sleeping difficulties
- cough
- depression
- stuffy nose
- headache
- diarrhea
If you experience the
following symptoms or any of those, call
your doctor immediately:
- skin rash
- numbness
- burning or pain in the hands or feet
- difficulty moving your hands and feet
- excessive tiredness
- vomiting
- weight loss
- fever
- chills
- swelling of the hands, feet, ankles, or lower legs
- painful red bumps on the skin
| |
|
|
|
|
